Acute Visual Disturbances and Ataxia Secondary to Attempted COVID-19 Prophylaxis With Ivermectin in a Nine-Year-Old

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 3; p. e35944
• Main Authors: Bhardwaj, Pranshu, Valladares, Daniel, Gutman, Colleen K, Lucas, Judith K, Kelly, Maria N
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 09.03.2023; Cureus
• Subjects: Antiparasitic agents; Ataxia; Auscultation; Blood; Children & youth; COVID-19; Creatinine; Disease prevention; Emergency medical care; Emergency Medicine; Hemoglobin; Hospitals; Neurology; Neurotoxicity; Neutrophils; Ophthalmology; Pediatrics; child maltreatment; covid-19; neurotoxicity syndromes; drug toxicities; ivermectin
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.35944

Ivermectin is an antiparasitic agent listed as an essential medication by the World Health Organization. Ivermectin utilization has increased due to the popular, though inaccurate, perception of its use in COVID-19 management. Poison Control Central calls regarding ivermectin toxicity have increased 245% since pre-pandemic baselines. This case study illustrates the clinical presentation of ivermectin toxicity in a nine-year-old child with acute vision changes and ataxia. The child was given 60 mg (1 mg/kg) of veterinary-grade ivermectin by a parent, 10 times the clinically recommended dose of 0.1 mg/kg, as prophylaxis after household exposure to COVID-19. Ten hours later, the child developed new-onset blurry vision, a perception of red dots in the peripheral vision, dizziness, and balance issues. Physical examination was notable for pulsating pupils, ataxia, and dysmetria. Symptoms resolved completely after 10 hours. Ivermectin ingestion is an important diagnostic consideration in children presenting with similar symptoms. We hope our case aids in the identification of ivermectin toxicity and hastens necessary supportive measures.